Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.44 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.43 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.42 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.42 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28087267 | 1.00 | TAAR1 (0.55) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL938702 | 0.98 | TAAR1 (0.57) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL28087397 | 0.98 | TAAR1 (0.57) | TAAR1GAAKMT2AMEN1CA12 | |
| Oxalic Acid SCHEMBL27962691 | 0.89 | GAA (0.52) | TAAR1GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13801229 | 0.87 | TAAR1 (0.53) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL13644447 | 0.87 | TAAR1 (0.57) | TAAR1GAAKMT2AMEN1CA12 | |
| Hydrochloric Acid SCHEMBL3770898 | 0.86 | TAAR1 (0.52) | TAAR1GAAKMT2AMEN1MAPT | |
| SCHEMBL12574171 | 0.84 | TAAR1 (0.53) | TAAR1GAAKMT2AMEN1CA12 | |
| SCHEMBL937041 | 0.84 | TAAR1 (0.53) | TAAR1GAAKMT2AMEN1MAPT | |
| SCHEMBL23374696 | 0.82 | TAAR1 (0.52) | TAAR1GAAKMT2AMEN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822727-B2 | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | claimed |
| EP-2518053-A1 | PROCESS FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | Arena Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| US-8168782-B2 | synthesis of lorcaserin | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | claimed |
| JP-2011513402-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2288585-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES RELATED TO THE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | Arena Pharmaceuticals, Inc. (US) | 2011-03-02 | — | — | EP | claimed |
| US-20110015438-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES RELATED TOTHE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5,-TETRAHYDRO-1H-3-BENZAZEPINE | ARENA PHARMACEUTICALS, INC. | 2011-01-20 | — | — | US | claimed |
| WO-2009111004-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES RELATED TO THE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | claimed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | claimed |
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | ARENA PHARMACEUTICALS, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-3485878-A1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | Arena Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | ARENA PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2611427-B1 | MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT | ARENA PHARM INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20100305316-A1 | PROCESSES FOR PREPARING (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES THEREOF | ARENA PHARMACEUTICALS, INC. | 2010-12-02 | — | — | US | disclosed |
| WO-2009111004-A1 | PROCESSES FOR THE PREPARATION OF INTERMEDIATES RELATED TO THE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE | ARENA PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463676-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | GAA 2568/4885CA2 2618/4885KCNH2 795/4885 |
| US-10226471-B2 | Modified-release dosage forms of 5-HT2C agonists useful for weight management | HTR2C, HTR2A, HTR3C | GAA 2568/4885CA2 2618/4885KCNH2 795/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | GAA 2708/4885CA2 2797/4885KCNH2 623/4885 |
| US-20190275055-A1 | Modified-Release Dosage Forms of 5-Ht2c Agonists Useful for Weight Management | HTR2C, HTR2A, HTR3C | GAA 2568/4885CA2 2618/4885KCNH2 795/4885 |
| US-20110015438-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES RELATED TOTHE 5-HT2C AGONIST (R)-8-CHLORO-1-METHYL-2,3,4,5,-TETRAHYDRO-1H-3-BENZAZEPINE | HTR2C, HTR3C, HTR3A | GAA 2965/4885CA2 3891/4885KCNH2 371/4885 |
| US-20100305316-A1 | PROCESSES FOR PREPARING (R)-8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES THEREOF | HTR2C, HTR3C, HTR3B | GAA 2376/4885CA2 3351/4885KCNH2 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.